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a  b  s  t  r  a  c  t
A  blood  collection  tube  (Cyto-Chex® BCT),  which  can stabilize  white  blood  cells  and immunogenic  mark-
ers  in  blood  samples,  was  investigated  for its ability  to inactivate  human  immunodeﬁciency  virus  (HIV)
and stabilize  HIV  for viral  load  quantitation.  Laboratory-adapted  HIV  strains  were  either treated  or
untreated  with  the stabilizing  reagent  present  in Cyto-Chex® BCT.  A  dilution  of  the  reagent  used to
treat  virus  was  1:66,  which  was  similar  to the  reagent  concentration  in  Cyto-Chex® BCT  device  when
blood  was  drawn  into  it. In another  experiment,  blood  was  drawn  from  HIV  patients  into  one  acid  citrate
dextrose  (ACD)  tube  and  one  Cyto-Chex® BCT.  At  indicated  time  points,  aliquots  were  taken  of  treated
and  untreated  viral  dilutions  and  from  plasma  of HIV-positive  patient  blood  samples  and  analyzed  using
reverse  transcriptase  and  TZM-bl  cell  assays  to determine  HIV inactivation.  In laboratory-adapted  HIVlood collection device strains  and  HIV-positive  patient  plasma,  HIV was  completely  inactivated  within  2  and  3  h of contact  with
a  1:66  dilution  of Cyto-Chex  reagent,  respectively.  Samples  from  HIV-positive  patient  plasma  showed
that  viral  load  was  stable  in  Cyto-Chex® BCT  for 7  days  at room  temperature.  Therefore,  it is concluded
that  the  chemical  reagent  present  in  the  Cyto-Chex® BCT  blood  collection  device  is  capable  of  complete
inhibition  of  HIV  infectivity  in  blood  samples  within  3  h  and stabilizing  the  viral  load  for  7  days  at  room
temperature.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.. Introduction
According to the World Health Organization 2012 estimates,
here are currently about 34 million people worldwide living with
uman immunodeﬁciency virus (HIV) (World Health Organization,
011 Progress Report). About two-thirds of those affected reside
n Sub-Saharan African countries where HIV infection is epidemic
World Health Organization, 2011 Progress Report). In spite of
he scale-up of available anti-retroviral treatment, there are yet
ver 2 million new infections each year. Many of those who
re infected are unaware of their HIV status. Such patients are
t highest risk of transmitting viruses through blood exposure
o health care providers during medical procedures. Although
∗ Corresponding author at: Research & Development Division, Streck Inc., 7002 S
09 Street, Omaha, NE 68128, USA. Tel.: +1 402 537 5282; fax: +1 402 537 5352.
E-mail address: rfernando@streck.com (M.R. Fernando).
166-0934     ©  2013 The Authors. Published by Elsevier B.V. 
ttp://dx.doi.org/10.1016/j.jviromet.2013.10.028
Open access under CC BY license.universal precautions are practiced in clinics and laboratories,
potentially health care providers can be exposed to infectious blood
by laboratory procedures. Blood samples from HIV  patients may
present a biohazard to laboratory workers via accidental needle
stick or through exposed mucosal membranes. Most central-
ized large laboratories in industrialized nations provide measures
that allow laboratory workers to perform their work in a safe
environment. However, many smaller clinical laboratories, espe-
cially those in developing nations, have very few equipment and
facilities to protect their laboratory workers from accidental expo-
sure to blood borne pathogens such as HIV (Hersberger et al.,
2004).
It has been reported that a number of incidents where labo-
ratory workers have been infected by HIV through occupational
exposure (Palca, 1987a,b). Therefore, there is an urgent need to
develop simple and economical procedures to inactivate viable
HIV particles rapidly and safely in a patient blood sample. This
would improve the safety of laboratory personnel, especially in
developing countries where HIV prevalence is high and laboratory
conditions are marginal. A number of laboratories have developed
treatments to inactivate HIV effectively in blood samples. These
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reatments include heating, gamma  irradiation and treatment of
lood samples with chemical agents such as Triton X-100, NP-
0, sodium hypochlorite, ozone, paraformaldehyde, glutaraldehyde
nd formaldehyde (Hersberger et al., 2004; Ukkonen et al., 1988;
ells et al., 1991). However, these treatments are often costly,
umbersome and may  have detrimental effects on blood analytes
uch as gamma irradiation and heat treatment, which are known
o inactivate some enzymes in the blood.
The gold standard for testing for HIV infection is to test for the
resence of antibodies against HIV (Greenwald et al., 2006). For
ollowing and monitoring patients’ disease progression, additional
ssays such as CD4 T-cell counts and HIV viral load in the blood
eed to be conducted regularly (Crowe et al., 2003). In order to
outinely carry out CD4 T-cell counts, blood drawn within 72 h is
equired to prevent T-cell loss. When blood is drawn for HIV viral
oad testing, plasma separation should be carried out within 6 h
f phlebotomy (Bergeron et al., 2002). Since developed countries
ave clinical laboratories readily available, specimens can usually
e tested immediately. However, this has been a major problem
or developing countries owing to the lack of laboratory facilities
s most testing sites are located in cities not readily accessible to
atients in rural areas. Due to a shortage of point-of-care testing
or CD4 count and viral load, large numbers of infected individuals
ho are most in need of regular monitoring do not receive it.
As an alternative to rapid T-cell analysis of blood samples, a
ommercially available blood collection tube has been introduced
hat contains Cyto-Chex reagent (Cyto-Chex® BCT). These tubes
reserve lymphocytes and have received FDA approval for mon-
toring the HIV panel of markers that includes CD3, 4, 8, 16/56,
9 and 45. Cyto-Chex® BCTs have also demonstrated efﬁciency in
reservation of other cell surface markers including CD23, 34, 38
nd HLA-DR in blood samples stored at room temperature for up
o 7 days (Warrino et al., 2005). Because the Cyto-Chex reagent
cts as a ﬁxative to stabilize cell surface markers, it is hypothesized
hat this reagent may  have potential use in other applications. This
tudy demonstrates that Cyto-Chex reagent not only effectively
nactivates HIV particles to ensure safe handling of the infected
lood but also stabilizes viral particles when analyzed for viral
oad after being stored at room temperature for up to 7 days
ost-collection.
. Materials and methods
.1. Blood donor recruitment
HIV-negative healthy blood donors were recruited with written
nformed consent from Streck Inc., Omaha, NE, USA. HIV-positive
atients were recruited from the University of Nebraska Medi-
al Center (UNMC), Omaha, NE, USA. This study was  approved by
he UNMC Institutional Review Board (IRB number 206-06-FB).
ritten informed consent was obtained from all donors after they
ere advised about the study objectives.
.2. Blood collection
HIV-negative healthy donor blood was drawn into acid citrate
extrose (ACD) tubes (BD Vacutainer®, Becton Dickinson, Franklin
akes, NJ, USA). From each HIV-positive patient, blood samples
ere drawn into two different blood collection tubes–one was  an
CD tube and the other was Cyto-Chex® BCT (Streck Inc., Omaha,
E, USA). Blood was mixed immediately after the draw by inverting
ubes 10 times. Healthy donor blood was transported from Streck
nc., Omaha NE to the Nebraska Center for Virology, University
f Nebraska Lincoln (NCV), Lincoln, NE, USA. HIV-positive patient
lood samples were transported from UNMC to the NCV. All bloodl Methods 196 (2014) 50– 55 51
samples were maintained at room temperature (20–25 ◦C) during
transportation and arrival at NCV. For all donors, the total elapsed
time between blood draw and complete plasma processing at NCV
was 3 h.
2.3. Determination of HIV inactivation by TZM-bl cell infectivity
assay
2.3.1. Cell culture
To determine viral inactivation, TZM-bl cells (NIH AIDS Research
and Reference Reagent Program catalog no. 8129) were used, which
are HeLa cells that stably express cell surface markers for HIV bind-
ing and cell entry. TZM-bl cells were maintained in Dulbecco’s
modiﬁed Eagle medium (DMEM) with 10% fetal bovine serum
(FBS, Hyclone, Thermo Fisher Scientiﬁc Inc., Waltham, MA,  USA),
100 U/mL penicillin and 100 g/mL streptomycin.
2.3.2. TZM-bl assay
Viable HIV virus particles have the ability to bind and infect
TZM-bl cells. Conversely, inactivated HIV lacks this ability. To deter-
mine HIV inactivation using the infectivity of virus, a previously
described TZM-bl cell-based assay was used (Monteﬁori, 2009). The
TZM-bl cell line stably expresses CD4, has CXCR4 and CCR5 recep-
tors and an integrated copy of HIV-1 long terminal repeat (LTR)
linked to a luciferase and -galactosidase (-gal) gene. Expression
of these indicator genes by the LTR promoter is activated in the
presence of Tat protein, which is synthesized by the infecting virus.
At least 24 h before the introduction of the virus, 2.5 × 104 TZM-bl
cells were seeded in each well of a 96 well plate. DEAE-Dextran
(ﬁnal concentration 40 g/mL) was added to the cultured TZM-bl
cells, inoculated with reagent-treated or untreated virus and incu-
bated for 48 h. Cells were then ﬁxed and stained to observe for blue
cells as a result of the expression of -gal indicator gene. Blue cells
in the entire well were counted and the normalized percentage of
inactivation was calculated using the following equation:
T
U
× 100 = normalized % inactivation
where number of blue cells in untreated group, U; and number of
blue cells in treated group, T.
2.3.3. Effect of Cyto-Chex reagent on HIV determined by TZM-bl
assay
Laboratory-adapted virus strains of NL4-3 (clade B) and 1084i
(clade C) were used and the concentrations adjusted to get the
desired viral titer in order to simulate a wide range of patient
viral load levels. These concentrations ranged from 103 to 105
viral copies/mL and were incubated with or without Cyto-Chex
reagent (two dilutions of Cyto-Chex reagent; 1:66 and 1:233) at
room temperature. Aliquots (5 L) of treated or untreated virus
were removed from the incubation mixture at 2, 6, 12 and 24 h
and inactivation determined by viral infectivity using TZM-bl cell
assay as described in Section 2.3.2.
HIV-positive blood samples were used to study the effect of
Cyto-Chex reagent on HIV viral particles isolated from patient
plasma. At the NCV, blood samples in ACD tubes and Cyto-Chex®
BCTs from each patient were centrifuged at 300 × g for 20 min  and
the plasma was transferred to a new tube. To pellet viruses in
plasma, 1 mL  of plasma was  transferred into a new tube and cen-
trifuged at 18,300 × g at 4 ◦C for 2 h. The virus pellet was washed
twice with PBS and re-suspended in DMEM containing DEAE-
Dextran and virus inactivation was determined by detecting the
infectivity of viruses using TZM-bl cell assay as described in Section
2.3.2.
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Table 1
Inactivation of laboratory-adapted HIV strains, clades B and C, by Cyto-Chex
reagent. Strains clade B and C were incubated with two different dilutions of
Cyto-Chex reagent for the indicated times and virus infectivity was measured
using TZM-bl inactivation assay by counting the number of blue cells. The nor-
malized percentage of inactivation was  calculated using the following equation:
((U − T)/U) × 100 = normalized % inactivation, where U, number of blue cells in
untreated group; T, number of blue cells in treated group.
Time of incubation Reagent dilution
factor 1:233
Reagent dilution
factor 1:66
Normalized % inactivation of HIV clade B
2  h 95.5 100
6  h 100 100
12 h 100 100
24 h 100 100
Normalized % inactivation of HIV clade C
2  h 81 100
6  h 99.5 1002 E. Kwon et al. / Journal of Vir
.4. Determination of HIV inactivation by reverse transcriptase
nzyme activity and HIV LTR DNA ampliﬁcation assays
.4.1. Effect of Cyto-Chex reagent on HIV determined by reverse
ranscriptase activity assay
To conﬁrm that HIV inactivation was complete in Cyto-Chex
eagent-treated patient blood samples, two previously described
ethods were used. The ﬁrst method is based on reverse transcrip-
ase (RT) activity measurement of cell culture medium (Hoffman
t al., 1985). In this method, HIV inactivation is determined by HIV
nfectivity by co-cultivating peripheral blood mononuclear cells
PBMCs) obtained from HIV patient blood with PBMCs from healthy
onors and assaying culture supernatant for RT activity. Increased
T activity in cell culture medium is an indication of the presence
f viable HIV present in patient blood sample.
PBMCs were isolated from healthy donor and HIV patient
lood by centrifuging at 300 × g, for 30 min  at 4 ◦C using Ficoll
1.077 g/mL). PBMCs obtained from healthy donors (1 × 106 cells)
ere grown in RPMI-1640 cell culture medium (Sigma–Aldrich,
t. Louis, MO,  USA) which contained 10% FBS, antibiotics and l-
lutamine and incubated at 37 ◦C with 5% CO2. Healthy PBMCs
ere stimulated with phytohemagglutinin, (PHA) (5 g/mL) for
8 h before co-culture with HIV patient PBMCs (1 × 106 cells).
fter 4 days of co-culturing, one half of the cell culture medium
as replaced with fresh medium containing Interleukin 2 (IL-2),
20 IU/mL) and media replacement repeated every 4 days up to 21
ays. An aliquot of medium co-cultures was taken at days 4, 8 12, 16
nd 21 and ﬁltered through a 0.45 M ﬁlter before conducting the
T assay. Untreated human PBMCs from HIV-negative donors were
sed as negative controls. The amount of RT activity in 10 L of cell
ulture medium was determined by the [3H]thymidine incorpora-
ion assay as previously described (Hoffman et al., 1985) using a
icroplate scintillation counter (PerkinElmer, Waltham, MA,  USA).
.4.2. Effect of Cyto-Chex reagent on HIV determined by HIV LTR
NA ampliﬁcation assay
The other method used to determine the HIV inactivation in
atient blood samples is based on ampliﬁcation of HIV LTR DNA
xtracted from co-cultured patient PBMCs. Brieﬂy, HIV-1 DNA was
xtracted from co-cultured PBMCs and the LTR region was  ampli-
ed as previously described (Yun et al., 2002) and detected by
garase gel electrophoresis.
.5. Effect of Cyto-Chex reagent on HIV viral load at room
emperature storage for 7 days
Blood samples from HIV patients in ACD tubes and Cyto-Chex®
CT were stored at room temperature. Aliquots of blood were
emoved from both tube types on day 1 and another aliquot was
emoved from Cyto-Chex® BCT on day 7. Plasma was separated
rom blood as described earlier. Plasma (1 mL)  collected from blood
n ACD and Cyto-Chex® BCT tubes was centrifuged at 18,300 × g
or 2 h to pellet the virus. This viral pellet was used to extract
iral RNA using the QIAamp Viral RNA Mini Kit (Qiagen, Santa
larita, CA, USA) with minor modiﬁcations to manufacture’s rec-
mmended protocol. The ﬁrst modiﬁcation of the manufacturer’s
uggested protocol occurred after centrifugation. The viral pellet
as re-suspended in 140 L of 1× PBS, lysed using 140 L of AVL
uffer and 140 L of Proteinase K was added. The second modiﬁ-
ation was made after the Proteinase K digestion step, when the
ysates were incubated in a thermomixer at 1300 rpm at 60 ◦C for
 h and centrifuged at 150 × g for 20 min. The remaining steps were
er the manufacturer’s suggested protocol.
Quantitation of plasma HIV viral load was done using a previ-
usly described reverse transcriptase real-time PCR protocol (Yun
t al., 2002). The only modiﬁcation to this protocol was  that the12 h 100 100
24 h 100 100
3′ end of the probe was labeled using Black Hole Quencher. The
AcroMetrix® HIV-1 Panel IU/mL (Applied Biosystems, Foster City,
CA, USA) was used as the viral load measurement standard.
3. Results
3.1. Cyto-Chex reagent inactivates HIV
HIV can be classiﬁed into different subtypes or clades based on
the amino acid sequences of the viral envelope glycoproteins. Clade
B is prevalent in the Western World but there are a number of clades
present in Sub-Saharan Africa. Clade C, the most prevalent subtype
in that region, is responsible for over 50% of new infections glob-
ally. Since HIV clades differ in their properties, including infectivity,
the effectiveness of the Cyto-Chex reagent was  tested against both
clade B and C. To investigate whether HIV can be inactivated in
Cyto-Chex® BCT tubes due to the presence of Cyto-Chex reagent,
laboratory strains of HIV clade B and HIV clade C were incubated
separately with Cyto-Chex reagent for 2, 6, 12 and 24 h (Table 1).
Since undiluted Cyto-Chex reagent was toxic to TZM-bl indicator
cells, Cyto-Chex reagent was diluted in these inactivation studies.
The Cyto-Chex® BCT device is a 5 mL  blood collection tube which
contains 75 L of Cyto-Chex reagent. When 5 mL  blood is drawn
into the tube, the Cyto-Chex reagent gets diluted 66 times. This
dilution has no adverse effect on TZM-bl cells and was  used as
the dilution starting point. A more dilute concentration of 1:233
was chosen to further dilute Cyto-Chex reagent and test inactiva-
tion. The normal Cyto-Chex reagent ratio of 1:66 present in 5 mL
of blood drawn into Cyto-Chex® BCT completely inactivated both
clade B and C at 2 h (Table 1). A 1:233 dilution of Cyto-Chex reagent
completely inactivated clade B by 6 h. To achieve complete inactiva-
tion of clade C using the lower concentration of Cyto-Chex reagent,
12 h was  required (Table 1). Further, to investigate if viral inacti-
vation was  dependent on titer, a range of HIV titers were tested.
The results conﬁrmed that viral inactivation was  not dependent on
virus titer. As summarized in Table 2, virus titers ranging from 103
to 105 HIV particles/mL were completely inactivated by the Cyto-
Chex reagent as measured by the TZM-Bl infectivity assay. This was
observed in both clade B and C strains.
Since laboratory-adapted HIV strains were completely inactiv-
ated by Cyto-Chex reagent, there was interest in investigating
whether HIV in patients’ plasma could also be inactivated in Cyto-
Chex® BCT. Therefore, blood was  collected from four HIV-positive
patients into Cyto-Chex® BCTs and ACD tubes. The four patients
exhibited different plasma viral titers and CD4 counts as summa-
rized in Table 3. After blood collection, plasma was  isolated and
E. Kwon et al. / Journal of Virologica
Table 2
Inactivation of different titers of laboratory-adapted HIV strains, clades B and C,
by Cyto-Chex reagent. Strains clades B and C were incubated with 1:66 dilution
of  Cyto-Chex® BCT reagent for the indicated times and virus infectivity was  mea-
sured using TZM-bl inactivation assay by counting the number of blue cells. The
normalized percentage of inactivation was calculated using the following equa-
tion: ((U − T)/U) × 100 = normalized % inactivation, where U, number of blue cells
in  untreated group; T, number of blue cells in treated group.
Time of incubation % inactivation of different titers of HIV clade B & C
1 × 103 1 × 104 1 × 105
Clade B Clade C Clade B Clade C Clade B Clade C
2 h 100 100 100 100 100 100
6  h 100 100 100 100 100 100
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24  h 100 100 100 100 100 100
sed to harvest the viral pellet by centrifugation. The viral pellet
as re-suspended in tissue culture medium and TZM-bl cells were
nfected with the re-suspended virus (Table 3). By 3 h after blood
ollection in Cyto-Chex® BCT, it is observed that 100% of the viral
articles were inactivated in all four patient samples.
To conﬁrm further the observation of complete viral inactiva-
ion, patient blood was tested for the presence of any residual
nfectious viral particles by co-cultivation. PBMCs from all four
IV patients were harvested at 3 h in blood collection tubes and
o-cultured with healthy donor PBMCs for at least 20 days. Super-
atants were analyzed for the presence of HIV by measuring RT
ctivity every 4 days (Fig. 1). Increasing levels of RT activity was
bserved only after co-culturing PBMCs harvested from blood col-
ected into ACD tubes. No RT activity could be detected in PBMCs
arvested from blood samples collected in Cyto-Chex® BCT, sug-
esting that the viral particles were completely inactivated by
yto-Chex reagent.
For further conﬁrmation, DNA was isolated from PBMCs that
ad been co-cultured ≥20 days with patients’ PBMCs and the LTR
egion was ampliﬁed by PCR (data not shown). When the PCR prod-
cts were electrophoresed on an agarose gel, a speciﬁc band for
TR (190 bp) was observed for all four PBMC samples collected
n parallel in ACD tubes. No LTR-speciﬁc bands were observed in
ny ampliﬁcation of HIV DNA in PBMCs that were co-cultured with
BMCs harvested from blood collected in Cyto-Chex® BCT.
.2. HIV viral load remains stable in Cyto-Chex® BCTs
The stability of HIV viral load in blood drawn into Cyto-Chex®
CTs was investigated. As depicted in Fig. 2, plasma viral load for
ll four patients were stable in Cyto-Chex® BCT for 7 days at room
emperature, suggesting that even though the viral particles are
ompletely non-infectious, the viral RNA was rendered stable and
here was no loss of viral copy number even after 7 days at room
emperature.
able 3
nactivation of HIV in blood samples from HIV-positive patients using Cyto-Chex®
CT reagent. Blood was drawn from each HIV patient into one ACD tube and one
yto-Chex® BCT. Blood samples were processed 3 h post-blood draw and normal-
zed % inactivation of HIV was determined using TZM-bl inactivation assay. The
ormalized percentage of inactivation was calculated using the following equa-
ion: ((U − T)/U) × 100 = normalized % inactivation, where U, number of blue cells
n  untreated group; T, number of blue cells in treated group.
HIV patient ID HIV viral load/mL
plasma
CD4 count/L % HIV inactivation (3 h
post-blood draw)
12–14 52,223 323 100
12–16 53,971 211 100
12–17 312,775 5 100
12–19 226,746 315 100l Methods 196 (2014) 50– 55 53
4. Discussion
The Cyto-Chex® BCT device is an FDA-approved blood collection
tube for the preservation of HIV panel of T-cell surface markers CD3,
4, 8, 16/56, 19 and 45 in blood samples stored at room temperature
for up to 7 days. Further, Warrino et al. (2005) have shown Cyto-
Chex® BCT’s ability in the preservation of other cell surface markers
including CD23, 34, 38 and HLA-DR in blood samples under the
same conditions. Since these tubes are useful in preserving blood
specimens in both healthy donors and HIV-infected donors, they
can be used to transport blood samples to laboratories to perform
CD4 analyses for HIV-infected individuals at a later time.
In this study, the Cyto-Chex reagent was  investigated for its
ability to not only inactivate HIV-1 but also at the same time sta-
bilize plasma HIV-1 particles. These properties would allow for
safer handling of infectious specimens by laboratory workers while
also preserving viral RNA for accurate measurement of viral load
even after 7 days of storage at room temperature. It was  shown
that viral particles could be completely inactivated in 3 h after
exposure to a 1:66 dilution of Cyto-Chex reagent in whole blood.
A number of viral assays were used, including TZM-bl cell and
reverse-transcriptase enzyme activity-based assays, to ensure that
no residual infectious viral particles are present in blood after incu-
bation with Cyto-Chex reagent. For the cell-based TZM-bl assay,
complete inactivation was  observed with a lower concentration of
the Cyto-Chex reagent (1:233) rather than the concentration (1:66)
that is used when blood is collected in the Cyto-Chex® BCT.
The results also indicate that both clade B and C viruses were
rendered inactive by the Cyto-Chex reagent under a wide range
of viral titer. Using a range from 103 to 104 particles/mL, which
were chosen to mimic  viral titers typically found in patient samples,
inactivation was  effectively complete following reagent incubation
for as little as 2 h. Taken together, the results provide strong evi-
dence that the Cyto-Chex reagent is a fast acting, potent reagent
that renders a safer blood sample in as little as 2 h.
At this time, the mechanism of HIV inactivation by the Cyto-
Chex reagent is not fully understood. It is known that ﬁxative
reagents such as formaldehyde can inactivate viruses (Gard, 1957;
Goldstein and Tauraso, 1970) and this inactivation might result
from the ﬁxative reagents’ ability to cross-link with nucleic acids
and proteins (Sutherland et al., 2008). Wu et al. (2002) showed
that these modiﬁcations are reversible with Proteinase K and heat
treatment. Since blood cells treated with Cyto-Chex reagent also
respond similarly to Proteinase K and heat treatment, it is specu-
lated that Cyto-Chex reagent stabilizes CD4 and other molecules
on T-cells by cross-linking. It is thus possible that viral surface
glycoproteins such as gp120 that are essential for CD4 receptor
binding become cross-linked to render HIV non-infectious. In addi-
tion to HIV, Cyto-Chex reagent may  also be able to cross-link other
potential blood borne pathogens, but veriﬁcation by further inves-
tigations would be necessary.
These viral inactivation results led to an interest in determining
whether the treated viral RNA is stable to be subsequently used to
determine viral load accurately. It was  found that when viral load
was determined, HIV-1-infected patient samples drawn into Cyto-
Chex® BCT were clinically similar to those obtained with blood
collected in regular ACD tubes after one day post-treatment by
the Cyto-Chex reagent. Moreover, the patients’ whole blood sam-
ples collected in Cyto-Chex® BCT after 7 days at room temperature
showed similar viral loads as on one day post-collection. The results
show that even with 7 days of incubation at room temperature, HIV-
1 plasma viral loads were unaffected and comparable viral levels
were detected. Yet it was  observed that Cyto-Chex® BCT reagent is
a potent ﬁxative and minor modiﬁcations to the HIV-1 RNA extrac-
tion protocol are needed. An additional Proteinase K digestion was
introduced and an extra step of heat treatment of RNA was added.
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T  activity of the negative control, untreated PBMCs obtained from HIV negative he
hese additional steps were necessary to achieve comparable RNA
xtraction efﬁciencies in samples collected in Cyto-Chex® BCT. The
ffectiveness of these extra steps provides further evidence that
ross-linking has occurred, since they are known modes of cross-
ink reversal. These modiﬁcations to the RNA extraction protocol
dd about 2 h to the sample processing time.
The use of anti-retroviral therapy (ART) has dramatically
hanged the HIV/AIDS epidemic–treated individuals are surviving
uch longer and most are able to live a normal life. However,
hese patients need to be monitored regularly for their CD4 T-
ell counts and blood viral load to determine the effectiveness
f ART. Any increase in viral load or decreases in CD4 count are
ig. 2. Effect of storage of HIV patient blood in Cyto-Chex® BCT on viral load stability as d
atient into one Cyto-Chex® BCT and one ACD tube. Aliquots of blood were removed at i
as  determined using RT-qPCR as described in Section 2. Error bars indicate SD. n = 5. as determined by reverse transcriptase (RT) assay. Blood was drawn from each HIV
-Chex® BCT () and ACD () tubes within 3 h of blood draw and co-cultured with
om Cyto-Chex® BCT and ACD and co-cultured with normal PBMCs. X, indicates the
donors.
considered to be indicators of treatment failure, possibly due to
the emergence of drug-resistant mutant HIV. Such monitoring is
essential so that alternative ART regimens can be implemented to
suppress the resistant viruses. With the recent scale-up of free-
of-charge ART in developing countries in Africa, the number of
treated HIV-infected individuals has dramatically increased in the
past several years; concurrently, the need for routine monitoring
of treated individuals with CD4 counting and viral load assessment
has increased. With access to laboratories for regular monitoring
of HIV-1 infected patients not always readily available, a method
of sample stabilization that permits sufﬁcient time for transport to
clinical laboratories at room temperature is a much needed option.
etermined by reverse transcription real-time PCR. Blood was  drawn from each HIV
ndicated days, the plasma separated and HIV viral load or HIV viral concentration
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